Stephan Schann

Company: Domain Therapeutics

Job title: Chief Scientific Officer

Seminars:

CCR8: Great Expectations 1:30 pm

CCR8 is emerging as the next hot immuno-oncology target DT-7012: discovery of a highly differentiated anti-CCR8 depleting antibody DT-7012 is about to enter the clinicRead more

day: Conference Day Two